Yahoo
OTC Markets OTCQB - Delayed Quote USD

Raphael Pharmaceutical Inc. (RAPH)

1.5100 0.0000 (0.00%)
As of October 30 at 5:00:00 PM EDT. Market Open.
Chart Range Bar
Loading chart for RAPH
  • Previous Close 1.5100
  • Open 1.5100
  • Bid 0.0601 x 2000000
  • Ask 1.5000 x 60000
  • Day's Range 1.5100 - 1.5100
  • 52 Week Range 0.7480 - 1.5100
  • Volume 100
  • Avg. Volume 1
  • Market Cap (intraday) 30.466M
  • Beta (5Y Monthly) 1.93
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

Raphael Pharmaceutical Inc., a pharmaceutical drug research and development company, focuses on the discovery and clinical development of life-improving drug therapies based on cannabinoids. The company develops lead product candidate for the treatment of rheumatoid arthritis. It also intends to develop cannabinoid-based drug products for the treatment of oncology indications and other autoimmune diseases. Raphael Pharmaceutical Inc., is headquartered in Jaffa, Israel.

www.raphaelpharmaceutical.com

--

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RAPH
7.86%
S&P 500 (^GSPC)
11.39%

1-Year Return

RAPH
51.00%
S&P 500 (^GSPC)
11.48%

3-Year Return

RAPH
47.19%
S&P 500 (^GSPC)
76.61%

5-Year Return

RAPH
31.36%
S&P 500 (^GSPC)
64.67%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -3,131.76%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -980k

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    254.12k

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: